title: Optimization of fast dissolving etoricoxib tablets prepared by sublimation technique.
abstract: The purpose of this investigation was to develop fast dissolving tablets of etoricoxib. Granules containing etoricoxib, menthol, crospovidone, aspartame and mannitol were prepared by wet granulation technique. Menthol was sublimed from the granules by exposing the granules to vacuum. The porous granules were then compressed in to tablets. Alternatively, tablets were first prepared and later exposed to vacuum. The tablets were evaluated for percentage friability and disintegration time. A 3(2) full factorial design was applied to investigate the combined effect of 2 formulation variables: amount of menthol and crospovidone. The results of multiple regression analysis indicated that for obtaining fast dissolving tablets; optimum amount of menthol and higher percentage of crospovidone should be used. A surface response plots are also presented to graphically represent the effect of the independent variables on the percentage friability and disintegration time. The validity of a generated mathematical model was tested by preparing a checkpoint batch. Sublimation of menthol from tablets resulted in rapid disintegration as compared with the tablets prepared from granules that were exposed to vacuum. The optimized tablet formulation was compared with conventional marketed tablets for percentage drug dissolved in 30 min (Q(30)) and dissolution efficiency after 30 min (DE(30)). From the results, it was concluded that fast dissolving tablets with improved etoricoxib dissolution could be prepared by sublimation of tablets containing suitable subliming agent.
authors.affiliation: Department of Pharmaceutics and Pharmaceutical Technology, Shri Sarvajanik Pharmacy College, Mehsana - 384 001, India.
authors.forename: D M
authors.initials: DM
authors.lastname: Patel
authors.forename: M M
authors.initials: MM
authors.lastname: Patel
references.citation: J Pharm Pharmacol. 1975 Jan;27(1):48-9
references.pmid: 235616
references.citation: J Control Release. 2005 Dec 5;109(1-3):203-10
references.pmid: 16260059
references.citation: Gastroenterol Clin North Am. 1992 Sep;21(3):631-41
references.pmid: 1516961
references.citation: J Pharmacol Exp Ther. 2001 Feb;296(2):558-66
references.pmid: 11160644
references.citation: Drug Dev Ind Pharm. 2006 Apr;32(4):437-42
references.pmid: 16638681
references.citation: Drug Dev Ind Pharm. 2007 May;33(5):505-11
references.pmid: 17520441
references.citation: Chem Pharm Bull (Tokyo). 1996 Nov;44(11):2121-7
references.pmid: 8945778
references.citation: AAPS PharmSciTech. 2006 Jun 16;7(2):E55
references.pmid: 16796372
references.citation: AAPS PharmSciTech. 2004 Apr 26;5(3):e36
references.pmid: 15760070
references.citation: Drugs. 2002;62(18):2637-51; discussion 2652-3
references.pmid: 12466002
references.citation: Chem Pharm Bull (Tokyo). 2006 Jan;54(1):99-102
references.pmid: 16394558